Navigation Links
Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
Date:8/19/2013

OKLAHOMA CITY, Aug. 19, 2013 /PRNewswire/ -- Selexys Pharmaceuticals Corporation, a privately held biopharmaceutical company that is developing therapies to treat inflammatory and thrombotic diseases, today announced that enrollment has been initiated in SUSTAIN, a Phase II, multicenter, randomized, placebo-controlled, double-blind, 12-month study to assess safety and efficacy of the anti-P-selectin monoclonal antibody SelG1 with or without hydroxyurea therapy in sickle cell disease patients with sickle cell-related pain crises.

The SUSTAIN trial will randomize approximately 174 patients to receive high dose SelG1, low dose SelG1 or placebo in the presence or absence of hydroxyurea therapy, the current standard of treatment. The study will examine the effectiveness of SelG1 in reducing the rate of sickle cell-related pain crises in each active dose level as compared to placebo. The study will be conducted in approximately 60 centers throughout the U.S. Further information on this trial is available at clinicaltrials.gov (NCT01895361).

"With the limited therapies available to patients with sickle cell disease, this trial with a novel P-selectin inhibitor is particularly exciting. Not only does it have the potential to improve the clinical outcomes in patients, its effects may be additive or synergistic with those of hydroxyurea, the only drug currently approved by the FDA for treatment of complications due to sickle cell disease," stated Dr. Kenneth Ataga, Lead Investigator and Associate Professor of Medicine in the Division of Hematology/Oncology, University of North Carolina at Chapel Hill.

"Data from preclinical sickle cell disease models suggest that blockade of P-selectin effectively prevents the painful stoppage of circulation in small blood vessels called vasoocclusion and maintains patent blood flow," stated Dr. Russell Rother, Selexys Executive Vice-President and Chief Operating Officer. "In addition, results from our recently completed Phase I study indicate that SelG1 is well tolerated in healthy human subjects. We now look forward to investigating its safety and efficacy in the sickle cell disease patient population."

SelG1 prevents certain blood cells from binding to one another and to the blood vessel walls. By stopping these cell-cell interactions, SelG1 may prevent small blood vessels from becoming blocked and reduce the occurrence and severity of pain crises as well as downstream complications such as stroke, heart attack and organ failure in sickle cell patients.

"We are excited to initiate our second clinical study with SelG1 and to test its potential benefit in the sickle cell patient population," said Dr. Scott Rollins, President and Chief Executive Officer of Selexys. "The SUSTAIN study focuses on the ability of our novel anti-P-selectin antibody to reduce or prevent the occurrence of pain crises and thereby improve the lives of patients with sickle cell, a disease that largely affects African-Americans in the U.S."

About SelG1
SelG1 is an investigational humanized monoclonal antibody directed against P-selectin, a key member of the adhesion molecule family known as the selectins. In preclinical studies, inhibition of P-selectin has been shown to effectively prevent vasoocclusion by blocking critical cell-cell interactions that drive this process. Therapeutic blockade of P-selectin may therefore reduce or prevent vasoocclusive crises in patients with sickle cell disease. The SelG1 program for sickle cell disease is supported by Small Business Innovation Research (SBIR) fast-track award #5R44HL093893-02 and #2R44HL093893-03 through the National Heart, Lung and Blood Institute.

About Sickle Cell Disease
Sickle cell disease is an inherited, progressive, hematologic disease that affects over 100,000 people in the United States including one out of every 500 African-Americans, with one in 12 African-Americans a carrier of the sickle cell disease gene. Patients with sickle cell disease suffer anemia as well as vasoocclusive complications in which sickled red cells, white blood cells and platelets adhere to small vessels blocking blood flow to downstream organs. This vasoocclusive process results in intense pain and repeated hospitalizations. It also leads to progressive multi-organ dysfunction and premature death. Sickle cell disease is considered an orphan indication with major unmet clinical needs.

About Selexys Pharmaceuticals
Selexys Pharmaceuticals Corporation is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of inflammation, thrombosis and metastasis across a broad range of severe diseases. Selexys is also developing an antibody directed against PSGL-1 for the treatment of Crohn's disease, multiple myeloma, and other inflammatory disorders. In September 2012, Selexys completed a $25 million Series A equity financing, led by MPM Capital and entered into an agreement with Novartis Pharmaceuticals whereby Novartis was granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, following the successful completion of a Phase 2 clinical study in patients with sickle cell disease. Selexys is headquartered in Oklahoma City, OK. For additional information please visit our website at www.selexys.com. Company Contact:  Media Contact:Selexys Pharmaceuticals

Rx Communications GroupScott Rollins, Ph.D.

Eric GoldmanPresident and Chief Executive Officer

Vice President Public Relations405-319-8195

917-322-2563srollins@selexys.com 

egoldman@rxir.com


'/>"/>
SOURCE Selexys Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Selexys Pharmaceuticals Completes $23M Equity Financing and Signs Agreement With Global Pharmaceutical Company
2. Cadence Pharmaceuticals Comments on USPTOs Non-Final, Initial Office Action on Reexamination of Patent
3. Cadence Pharmaceuticals Appoints Laureen DeBuono to its Board of Directors
4. Inovio Pharmaceuticals Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
5. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
6. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
7. Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
8. Robbins Arroyo LLP Is Investigating the Directors and Officers of Navidea Biopharmaceuticals, Inc.
9. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
10. AcelRx Pharmaceuticals Reports Second Quarter 2013 Financial Results
11. ANI Pharmaceuticals Announces an Agreement for the Development and Marketing of an Oral Soft Gel Prescription Product with Sofgen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... -- Research and Markets has announced the addition of the ... Global Opportunity Analysis and Industry Forecast, 2014-2022" report to their offering. ... Vital signs monitoring market ... $5,491 million by 2022, growing at a CAGR of 5.8% from 2016 ... the leading regional market in global vital signs monitoring devices industry. The ...
(Date:1/18/2017)... Jan. 18, 2017  Adaptive Sound Technologies, Inc. (ASTI), the ... partnership with Hyatt Place Nashville/Downtown to deliver the best ... sleep therapy machines in over two hundred of its ... important parts of having a great stay is sleeping ... Hyatt Place Nashville/Downtown. "We,re pleased to be able to ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... ... Students interested in video can get a jump start on their education ... $1,000 scholarship and have his or her video posted on the GenCure website and ... with the winner announced on June 9. , The competition is designed to help ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sam & Associates Insurance Agency, a full ... clients in the California Bay Area, is launching a charity drive to raise awareness ... Heart disease is the primary killer of adult men and women in America, and ...
(Date:1/19/2017)... ... January 19, 2017 , ... Attorney Robert “RC” ... consecutive year donated money to the Triumph Over Kid Cancer foundation. Each year, 175,000 ... of those children. James saw firsthand the effect of the critical funding gap for ...
(Date:1/19/2017)... ... January 19, 2017 , ... Connecticut Dermatology Group (CDG) is proud and excited ... compassionate dermatologist. Dr. Kim brings an extensive background in cutting-edge dermatology care and ... pleasure to welcome back Dr. Kim to the CDG team” said President and Managing ...
(Date:1/19/2017)... ... January 19, 2017 , ... Each ... Surgery Symposium, a conference where hundreds of surgeons from over fifteen different countries ... topics from cosmetic breast augmentation to breast reconstruction for breast cancer ...
Breaking Medicine News(10 mins):